Search

Your search keyword '"Zito, Laura"' showing total 26 results
Start Over Author "Zito, Laura"
26 results on '"Zito, Laura"'

1. P436: CUTTING-EDGE TRANSCRIPTOMICS TO IDENTIFY LEUKEMIA-INTRINSIC AND -EXTRINSIC CORRELATES OF IMMUNE ESCAPE AND POST-TRANSPLANTATION RELAPSE

Author

Edoardo Rovatti, Pier, primary, Punta, Marco, additional, Maria Naldini, Matteo, additional, Barcella, Matteo, additional, Zito, Laura, additional, Giovanni Carrabba, Matteo, additional, Bernardi, Massimo, additional, Peccatori, Jacopo, additional, Merelli, Ivan, additional, Gentner, Bernhard, additional, Ciceri, Fabio, additional, Vago, Luca, additional, and Toffalori, Cristina, additional

Published
2023
Full Text
View/download PDF

2. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications

Author

Russo, Antonio, Oliveira, Giacomo, Berglund, Sofia, Greco, Raffaella, Gambacorta, Valentina, Cieri, Nicoletta, Toffalori, Cristina, Zito, Laura, Lorentino, Francesca, Piemontese, Simona, Morelli, Mara, Giglio, Fabio, Assanelli, Andrea, Stanghellini, Maria Teresa Lupo, Bonini, Chiara, Peccatori, Jacopo, Ciceri, Fabio, Luznik, Leo, and Vago, Luca

Published
2018
Full Text
View/download PDF

3. Data from Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

Author

Gambacorta, Valentina, primary, Beretta, Stefano, primary, Ciccimarra, Martina, primary, Zito, Laura, primary, Giannetti, Kety, primary, Andrisani, Angela, primary, Gnani, Daniela, primary, Zanotti, Lucia, primary, Oliveira, Giacomo, primary, Carrabba, Matteo Giovanni, primary, Cittaro, Davide, primary, Merelli, Ivan, primary, Ciceri, Fabio, primary, Di Micco, Raffaella, primary, and Vago, Luca, primary

Published
2023
Full Text
View/download PDF

5. Abstract LB563: Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse

Author

Gambacorta, Valentina, primary, Beretta, Stefano, additional, Ciccimarra, Martina, additional, Zito, Laura, additional, Giannetti, Kety, additional, Andrisani, Angela, additional, Gnani, Daniela, additional, Zanotti, Lucia, additional, Oliveira, Giacomo, additional, Carrabba, Matteo G., additional, Cittaro, Davide, additional, Merelli, Ivan, additional, Ciceri, Fabio, additional, Di Micco, Raffaella, additional, and Vago, Luca, additional

Published
2022
Full Text
View/download PDF

6. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

Author

Toffalori, Cristina, Zito, Laura, Gambacorta, Valentina, Riba, Michela, Oliveira, Giacomo, Bucci, Gabriele, and Barcella, Matteo

Subjects
Transcription (Genetics) -- Research, Immunotherapy -- Usage, Hematopoietic stem cell transplantation -- Usage, Cancer patients -- Health aspects, Acute myelocytic leukemia -- Care and treatment -- Genetic aspects, Biochemistry, Antigens, T cells, Cancer treatment, Surgery, Recurrence (Disease), Motor vehicle drivers, Biological response modifiers, Myeloid leukemia, Explosions, Genes, Interferon, Gene expression, Biological sciences, Health
Abstract

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-[gamma] or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies. Post-transplantation relapse in acute myeloid leukemia patients without genomic loss of HLA is driven by transcriptional alterations in antigen presentation and T cell costimulation genes., Author(s): Cristina Toffalori [sup.1] , Laura Zito [sup.1] , Valentina Gambacorta [sup.1] [sup.2] , Michela Riba [sup.3] , Giacomo Oliveira [sup.1] [sup.4] [sup.19] , Gabriele Bucci [sup.1] [sup.3] , Matteo [...]

Published
2019
Full Text
View/download PDF

7. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

Author

Gambacorta, Valentina, primary, Beretta, Stefano, additional, Ciccimarra, Martina, additional, Zito, Laura, additional, Giannetti, Kety, additional, Andrisani, Angela, additional, Gnani, Daniela, additional, Zanotti, Lucia, additional, Oliveira, Giacomo, additional, Carrabba, Matteo Giovanni, additional, Cittaro, Davide, additional, Merelli, Ivan, additional, Ciceri, Fabio, additional, Di Micco, Raffaella, additional, and Vago, Luca, additional

Published
2022
Full Text
View/download PDF

10. Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Author

Rovatti, Pier Edoardo, primary, Zito, Laura, primary, Draghi, Eleonora, primary, Herrmann, Monika, primary, Marcinek, Anetta, primary, Brauchle, Bettina, primary, Covino, Cesare, primary, Di Bono, Mattia, primary, Carrabba, Matteo Giovanni, primary, Bernardi, Massimo, primary, Hopfner, Karl-Peter, primary, Toffalori, Cristina, primary, Ciceri, Fabio, primary, Subklewe, Marion, primary, and Vago, Luca, primary

Published
2019
Full Text
View/download PDF

11. Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression

Author

Gambacorta, Valentina, primary, Gnani, Daniela, primary, Zito, Laura, primary, Beretta, Stefano, primary, Zanotti, Lucia, primary, Giacomo, Oliveira, primary, Cittaro, Davide, primary, Merelli, Ivan, primary, Ciceri, Fabio, primary, Di Micco, Raffaella, primary, and Vago, Luca, primary

Published
2019
Full Text
View/download PDF

12. Combining Whole Exome Sequencing and Rnaseq to Provide a Comprehensive Landscape of the Mechanisms of Post-Transplantation Leukemia Relapse

Author

Zanotti, Lucia, primary, Bucci, Gabriele, additional, Santaniello, Francesco, additional, Toffalori, Cristina, additional, Biancolini, Donatella, additional, Zapparoli, Ettore, additional, Zito, Laura, additional, Carrabba, Matteo Giovanni, additional, Stoelzel, Friedrich, additional, Bornhäuser, Martin, additional, Bernardi, Massimo, additional, Peccatori, Jacopo, additional, Bonini, Chiara, additional, Cittaro, Davide, additional, Lazarevic, Dejan, additional, Tonon, Giovanni, additional, Ciceri, Fabio, additional, and Vago, Luca, additional

Published
2018
Full Text
View/download PDF

13. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: Dynamics and clinical implications

Author

Russo, A, Oliveira, G, Berglund, S, Greco, R, Gambacorta, V, Cieri, N, Toffalori, C, Zito, L, Lorentino, F, Piemontese, S, Morelli, M, Giglio, F, Assanelli, A, Stanghellini, M, Bonini, C, Peccatori, J, Ciceri, F, Luznik, L, Vago, L, Russo, Antonio, Oliveira, Giacomo, Berglund, Sofia, Greco, Raffaella, GAMBACORTA, VALENTINA, Cieri, Nicoletta, Toffalori, Cristina, Zito, Laura, Lorentino, Francesca, Piemontese, Simona, Morelli, Mara, Giglio, Fabio, Assanelli, Andrea, Stanghellini, Maria Teresa Lupo, Bonini, Chiara, Peccatori, Jacopo, Ciceri, Fabio, Luznik, Leo, Vago, Luca, Russo, A, Oliveira, G, Berglund, S, Greco, R, Gambacorta, V, Cieri, N, Toffalori, C, Zito, L, Lorentino, F, Piemontese, S, Morelli, M, Giglio, F, Assanelli, A, Stanghellini, M, Bonini, C, Peccatori, J, Ciceri, F, Luznik, L, Vago, L, Russo, Antonio, Oliveira, Giacomo, Berglund, Sofia, Greco, Raffaella, GAMBACORTA, VALENTINA, Cieri, Nicoletta, Toffalori, Cristina, Zito, Laura, Lorentino, Francesca, Piemontese, Simona, Morelli, Mara, Giglio, Fabio, Assanelli, Andrea, Stanghellini, Maria Teresa Lupo, Bonini, Chiara, Peccatori, Jacopo, Ciceri, Fabio, Luznik, Leo, and Vago, Luca

Abstract

The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion of unmanipulated T cell-replete grafts. PT-Cy selectively eliminates proliferating alloreactive T cells, but whether and how it affects natural killer (NK) cells and their alloreactivity is largely unknown. Here we characterized NK cell dynamics in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature NK cells, according to PT-Cy-based protocols in 2 independent centers. In both series, we documented robust proliferation of donor-derived NK cells immediately after HSCT. After infusion of Cy, a marked reduction of proliferating NK cells was evident, suggesting selective purging of dividing cells. Supporting this hypothesis, proliferating NK cells did not express aldehyde dehydrogenase and were killed by Cy in vitro. After ablation of mature NK cells, starting from day 15 after HSCT and favored by the high levels of interleukin-15 present in patients' sera, immature NK cells (CD62L+NKG2A+KIR-) became highly prevalent, possibly directly stemming from infused hematopoietic stem cells. Importantly, also putatively alloreactive single KIR1 NK cells were eliminated by PT-Cy and were thus decreased in numbers and antileukemic potential at day 30 after HSCT. As a consequence, in an extended series of 99 haplo-HSCT with PT-Cy, we found no significant difference in progression-free survival between patients with or without predicted NK alloreactivity (42% vs 52% at 1 year, P = NS). Our data suggest that the majority of mature NK cells infused with unmanipulated grafts are lost upon PT-Cy administration, blunting NK cell alloreactivity in this transplantation setting

Published
2018

14. Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy

Author

Russo, Antonio, primary, Oliveira, Giacomo, additional, Berglund, Sofia, additional, Greco, Raffaella, additional, Gambacorta, Valentina, additional, Cieri, Nicoletta, additional, Toffalori, Cristina, additional, Zito, Laura, additional, Piemontese, Simona, additional, Morelli, Mara, additional, Giglio, Fabio, additional, Assanelli, Andrea Angelo, additional, Lupo Stanghellini, Maria Teresa, additional, Bonini, Chiara, additional, Peccatori, Jacopo, additional, Luznik, Leo, additional, Ciceri, Fabio, additional, and Vago, Luca, additional

Published
2016
Full Text
View/download PDF

15. Clinical and Biological Features Associated with Engraftment of Acute Myeloid Leukemia Patient-Derived Xenografts

Author

Oliveira, Giacomo, primary, Bucci, Gabriele, additional, Toffalori, Cristina, additional, Caserta, Carolina, additional, Crucitti, Lara, additional, Camisa, Barbara, additional, Greco, Raffaella, additional, Biavasco, Francesca, additional, Zanotti, Lucia, additional, Zito, Laura, additional, Garcia-Manteiga, Jose Manuel, additional, Lazarevic, Dejan, additional, Carrabba, Matteo Giovanni, additional, Bernardi, Massimo, additional, Bondanza, Attilio, additional, Bonini, Chiara, additional, Ciceri, Fabio, additional, and Vago, Luca, additional

Published
2016
Full Text
View/download PDF

16. HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics

Author

Gambacorta, Valentina, primary, Oliveira, Giacomo, additional, Zito, Laura, additional, Toffalori, Cristina, additional, Crucitti, Lara, additional, Noviello, Maddalena, additional, Mazzi, Benedetta, additional, Greco, Raffaella, additional, Lupo Stanghellini, Maria Teresa, additional, Carrabba, Matteo G, additional, Bernardi, Massimo, additional, Peccatori, Jacopo, additional, Fleischhauer, Katharina, additional, Bonini, Chiara, additional, Ciceri, Fabio, additional, and Vago, Luca, additional

Published
2015
Full Text
View/download PDF

18. Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation

Author

Toffalori, Cristina, primary, Riba, Michela, additional, Zito, Laura, additional, Barcella, Matteo, additional, Spinelli, Orietta, additional, Crucitti, Lara, additional, Cieri, Nicoletta, additional, Peccatori, Jacopo, additional, Bernardi, Massimo, additional, Bonini, Chiara, additional, Cittaro, Davide, additional, Lazarevic, Dejan, additional, Rambaldi, Alessandro, additional, Barlassina, Cristina, additional, Stupka, Elia, additional, Ciceri, Fabio, additional, Fleischhauer, Katharina, additional, and Vago, Luca, additional

Published
2014
Full Text
View/download PDF

19. Effects of transmembrane region variability on cell surface expression and allorecognition of HLA-DP3

Author

Crivello, Pietro, primary, Lauterbach, Nina, additional, Zito, Laura, additional, Sizzano, Federico, additional, Toffalori, Cristina, additional, Marcon, Jessica, additional, Curci, Laura, additional, Mulder, Arend, additional, Wieten, Lotte, additional, Zino, Elisabetta, additional, Voorter, Christien E.M., additional, Tilanus, Marcel G.J., additional, and Fleischhauer, Katharina, additional

Published
2013
Full Text
View/download PDF

21. Optimal Thalassemia Free Survival and Minimal Regimen Related Toxicity in 50 Consecutive Transplants of High Risk Beta Thalassemia Pediatric Patients Using Myelablative Therapy with Intravenous Busulphan.

Author

Marktel, Sarah, primary, Chiesa, Robert, additional, Cappelli, Barbara, additional, Roccia, Tito, additional, Frugnoli, Ilaria, additional, Noè, Anna, additional, Biral, Erika, additional, Crocchiolo, Roberto, additional, Evangelio, Costanza, additional, Fossati, Marco, additional, Napolitano, Sara, additional, Soliman, Clara, additional, Cursi, Laura, additional, Cattaneo, Federica, additional, Zito, Laura, additional, Fiori, Rossana, additional, Fleischhauer, Katharina, additional, Miniero, Roberto, additional, Ciceri, Fabio, additional, and Roncarolo, Maria Grazia, additional

Published
2008
Full Text
View/download PDF

23. Gaza.

Author

ZITO, LAURA JEAN

Subjects
COLOR photography, MUSLIMS in art
Published
2022

25. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

Author

Valentina Gambacorta, Stefano Beretta, Martina Ciccimarra, Laura Zito, Kety Giannetti, Angela Andrisani, Daniela Gnani, Lucia Zanotti, Giacomo Oliveira, Matteo Giovanni Carrabba, Davide Cittaro, Ivan Merelli, Fabio Ciceri, Raffaella Di Micco, Luca Vago, Gambacorta, Valentina, Beretta, Stefano, Ciccimarra, Martina, Zito, Laura, Giannetti, Kety, Andrisani, Angela, Gnani, Daniela, Zanotti, Lucia, Oliveira, Giacomo, Carrabba, Matteo Giovanni, Cittaro, Davide, Merelli, Ivan, Ciceri, Fabio, di Micco, Raffaella, and Vago, Luca

Subjects
Leukemia, Myeloid, Acute, Oncology, Recurrence, hemic and lymphatic diseases, Hematopoietic Stem Cell Transplantation, Histocompatibility Antigens Class II, Polycomb Repressive Complex 2, Humans, Tumor Escape, Chromatin, Epigenesis, Genetic
Abstract

Immune escape represents a major driver of acute myeloid leukemia (AML) reemergence after allogeneic hematopoietic cell transplantation (allo-HCT), with up to 40% of relapses prompted by nongenomic loss of HLA class II expression in leukemia cells. By integrative analysis of gene expression, DNA methylation, and chromatin accessibility in paired diagnosis/relapse primary samples and in the respective patient-derived xenografts (PDX), we identify the polycomb repressive complex 2 (PRC2) as a key epigenetic driver of this immune escape modality. We report that loss of expression of HLA class II molecules is accompanied by a PRC2-dependent reduction in chromatin accessibility. Pharmacologic inhibition of PRC2 subunits rescues HLA class II expression in AML relapses in vitro and in vivo, with consequent recovery of leukemia recognition by CD4+ T cells. Our results uncover a novel link between epigenetics and leukemia immune escape, which may rapidly translate into innovative strategies to cure or prevent AML posttransplantation relapse. Significance: Loss of HLA class II expression represents a frequent mechanism of leukemia posttransplantation relapse. Here we identify PRC2 as the main epigenetic driver of this immune escape modality and show that its chemical inhibition can reinstate a proficient graft-versus-leukemia effect, providing an innovative rationale for personalized epigenetic immunotherapies. See related commentary by Köhler and Zeiser, p. 1410. This article is highlighted in the In This Issue feature, p. 1397

Published
2022

26. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: Dynamics and clinical implications

Author

Maria Teresa Lupo Stanghellini, Raffaella Greco, Sofia Berglund, Leo Luznik, Francesca Lorentino, Giacomo Oliveira, Fabio Giglio, Andrea Assanelli, Mara Morelli, Valentina Gambacorta, Simona Piemontese, Jacopo Peccatori, Antonio Russo, Luca Vago, Nicoletta Cieri, Fabio Ciceri, Chiara Bonini, Cristina Toffalori, Laura Zito, Russo, Antonio, Oliveira, Giacomo, Berglund, Sofia, Greco, Raffaella, Gambacorta, Valentina, Cieri, Nicoletta, Toffalori, Cristina, Zito, Laura, Lorentino, Francesca, Piemontese, Simona, Morelli, Mara, Giglio, Fabio, Assanelli, Andrea, Stanghellini, Maria Teresa Lupo, Bonini, Chiara, Peccatori, Jacopo, Ciceri, Fabio, Luznik, Leo, Vago, Luca, Russo, A, Oliveira, G, Berglund, S, Greco, R, Gambacorta, V, Cieri, N, Toffalori, C, Zito, L, Lorentino, F, Piemontese, S, Morelli, M, Giglio, F, Assanelli, A, Stanghellini, M, Bonini, C, Peccatori, J, Ciceri, F, Luznik, L, and Vago, L

Subjects
medicine.medical_specialty, Cyclophosphamide, medicine.medical_treatment, Cell, Immunology, Hematopoietic stem cell transplantation, Biology, Biochemistry, 03 medical and health sciences, Interleukin 21, 0302 clinical medicine, Internal medicine, medicine, Transplantation, Hematology, Hematopoietic Stem Cell Transplantation, Cell Biology, Killer Cells, Natural, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Stem cell, 030215 immunology, medicine.drug
Abstract

The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion of unmanipulated T cell-replete grafts. PT-Cy selectively eliminates proliferating alloreactive T cells, but whether and how it affects natural killer (NK) cells and their alloreactivity is largely unknown. Here we characterized NK cell dynamics in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature NK cells, according to PT-Cy-based protocols in 2 independent centers. In both series, we documented robust proliferation of donor-derived NK cells immediately after HSCT. After infusion of Cy, a marked reduction of proliferating NK cells was evident, suggesting selective purging of dividing cells. Supporting this hypothesis, proliferating NK cells did not express aldehyde dehydrogenase and were killed by Cy in vitro. After ablation of mature NK cells, starting from day 15 after HSCT and favored by the high levels of interleukin-15 present in patients' sera, immature NK cells (CD62L+NKG2A+KIR-) became highly prevalent, possibly directly stemming from infused hematopoietic stem cells. Importantly, also putatively alloreactive single KIR+ NK cells were eliminated by PT-Cy and were thus decreased in numbers and antileukemic potential at day 30 after HSCT. As a consequence, in an extended series of 99 haplo-HSCT with PT-Cy, we found no significant difference in progression-free survival between patients with or without predicted NK alloreactivity (42% vs 52% at 1 year, P = NS). Our data suggest that the majority of mature NK cells infused with unmanipulated grafts are lost upon PT-Cy administration, blunting NK cell alloreactivity in this transplantation setting.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results